Bevacizumab (Avastin®; Genentech, Inc.; South San Francisco, CA), an anti-VEGF monoclonal antibody approved for use by the US Food and Drug Administration (FDA) in 2004, inhibits tumor angiogenesis and the growth and proliferation of human tumor cell lines [3, 4]. This evidence concerns the gene VEGFA and neoplasm.